Clinical Trial Detail

Contact

Missing content? – Request curation!

Request curation for specific Genes, variants, or PubMed publications.

Have questions, comments or suggestions? - Let us know!

Email us at : ckbsupport@jax.org

NCT ID NCT04696575
Title Lamivudine in Combination With Chemoimmunotherapy for the Treatment of Extensive Stage Small Cell Lung Cancer
Recruitment Recruiting
Gender both
Phase Phase II
Variant Requirements No
Sponsors Roswell Park Cancer Institute
Indications

lung small cell carcinoma

Therapies

Atezolizumab + Carboplatin + Etoposide + Lamivudine

Atezolizumab + Lamivudine

Age Groups: adult | senior
Covered Countries USA


No variant requirements are available.